MLICM
LFCR icon

Metropolitan Life Insurance Company (MetLife)’s Lifecore Biomedical LFCR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,434
Closed -$5.41K – 2490
2023
Q1 		$5.41K Sell
1,434
-280
-16% -$1.56K ﹤0.01% 2271
2022
Q4 		$11.1K Hold
1,714
– – ﹤0.01% 2256
2022
Q3 		$15.2K Hold
1,714
– – ﹤0.01% 2148
2022
Q2 		$17.1K Hold
1,714
– – ﹤0.01% 2119
2022
Q1 		$19.8K Sell
1,714
-4,107
-71% -$45.7K ﹤0.01% 2101
2021
Q4 		$64.6K Sell
5,821
-1,740
-23% -$16.9K ﹤0.01% 2666
2021
Q3 		$69.7K Buy
+7,561
New +$82.3K ﹤0.01% 2702
2021
Q1 		– Sell
-8,039
Closed -$87.2K – 2595
2020
Q4 		$87.2K Buy
8,039
+4,362
+119% +$45.1K ﹤0.01% 2408
2020
Q3 		$35.7K Sell
3,677
-4,925
-57% -$46.9K ﹤0.01% 2498
2020
Q2 		$68.5K Hold
8,602
– – ﹤0.01% 2450
2020
Q1 		$74.8K Buy
8,602
+1,097
+15% +$11.4K ﹤0.01% 2217
2019
Q4 		$84.9K Buy
7,505
+2,778
+59% +$29.6K ﹤0.01% 2415
2019
Q3 		$51.4K Sell
4,727
-4,816
-50% -$52.4K ﹤0.01% 2495
2019
Q2 		$89.4K Hold
9,543
– – ﹤0.01% 2360
2019
Q1 		$117K Hold
9,543
– – ﹤0.01% 2230
2018
Q4 		$113K Hold
9,543
– – ﹤0.01% 2192
2018
Q3 		$137K Hold
9,543
– – ﹤0.01% 2260
2018
Q2 		$142K Hold
9,543
– – ﹤0.01% 2139
2018
Q1 		$125K Hold
9,543
– – ﹤0.01% 2177
2017
Q4 		$120K Sell
9,543
-9,474
-50% -$120K ﹤0.01% 2207
2017
Q3 		$246K Sell
19,017
-1,178
-6% -$15.5K ﹤0.01% 2162
2017
Q2 		$300K Hold
20,195
– – ﹤0.01% 2069
2017
Q1 		$242K Hold
20,195
– – ﹤0.01% 2148
2016
Q4 		$279K Buy
20,195
+1,951
+11% +$27K ﹤0.01% 2136
2016
Q3 		$245K Sell
18,244
-2,696
-13% -$32.7K ﹤0.01% 2216
2016
Q2 		$225K Hold
20,940
– – ﹤0.01% 2243
2016
Q1 		$220K Hold
20,940
– – ﹤0.01% 2116
2015
Q4 		$248K Buy
20,940
+1,925
+10% +$23.6K ﹤0.01% 2091
2015
Q3 		$222K Sell
19,015
-1,165
-6% -$15.4K ﹤0.01% 2218
2015
Q2 		$291K Sell
20,180
-2,336
-10% -$33.7K ﹤0.01% 2138
2015
Q1 		$314K Hold
22,516
– – ﹤0.01% 1818
2014
Q4 		$311K Hold
22,516
– – ﹤0.01% 2101
2014
Q3 		$276K Hold
22,516
– – ﹤0.01% 2141
2014
Q2 		$281K Hold
22,516
– – ﹤0.01% 2261
2014
Q1 		$251K Hold
22,516
– – ﹤0.01% 2305
2013
Q4 		$273K Hold
22,516
– – ﹤0.01% 2250
2013
Q3 		$275K Hold
22,516
– – ﹤0.01% 2174
2013
Q2 		$297K Buy
+22,516
New +$311K ﹤0.01% 2052

Other funds holding LFCR

GRIM
Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return
WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VWA
Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s LFCR Position: Q2 2023 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Lifecore Biomedical (LFCR) in Q2 2023, closing a stake of 1,434 shares — an estimated $5.41K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in LFCR in Q2 2013 and held it in 38 quarters. The position peaked at $314K in Q1 2015. 75 funds tracked by Wall St. Rank hold LFCR as of Q2 2023.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Lifecore Biomedical position as of Q2 2023 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 1,434 Lifecore Biomedical shares in Q2 2023, an estimated $5.41K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Lifecore Biomedical in Q2 2013 and held it in 38 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Lifecore Biomedical position peaked at $314K in Q1 2015.
  • 75 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q2 2023.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2023, filed 10 Aug 2023.